BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tak E, Lee S, Lee J, Rashid M, Kim YW, Park J, Park WS, Shokat KM, Ha J, Kim SS. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells. Journal of Hepatology 2011;54:328-39. [DOI: 10.1016/j.jhep.2010.06.045] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Yun M, Choi AJ, Lee YC, Kong M, Sung JY, Kim SS, Eun YG. Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma. J Exp Clin Cancer Res 2018;37:264. [PMID: 30376862 DOI: 10.1186/s13046-018-0942-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
2 Natu A, Singh A, Gupta S. Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities. World J Hepatol 2021; 13(11): 1568-1583 [PMID: 34904030 DOI: 10.4254/wjh.v13.i11.1568] [Reference Citation Analysis]
3 Lohitesh K, Chowdhury R, Mukherjee S. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer Cell Int. 2018;18:44. [PMID: 29568237 DOI: 10.1186/s12935-018-0538-7] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 19.0] [Reference Citation Analysis]
4 Chen C, Lou T. Hypoxia inducible factors in hepatocellular carcinoma. Oncotarget 2017;8:46691-703. [PMID: 28493839 DOI: 10.18632/oncotarget.17358] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 15.5] [Reference Citation Analysis]
5 Hamiditabar M, Ali M, Bolek L, Vahdati G, Tworowska I, Delpassand ES. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors. Clin Nucl Med 2017;42:822-8. [PMID: 28832377 DOI: 10.1097/RLU.0000000000001818] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 Freeland MM, Angulo J, Davis AL, Flook AM, Garcia BL, King NA, Mangibin SK, Paul KM, Prosser ME, Sata N, Bentley JL, Olson LE. Sex differences in improved efficacy of doxorubicin chemotherapy in Cbr1+/− mice. Anti-Cancer Drugs 2012;23:584-9. [DOI: 10.1097/cad.0b013e3283512726] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
7 Kwon JH, Lee J, Kim J, Jo YH, Kirchner VA, Kim N, Kwak BJ, Hwang S, Song GW, Lee SG, Yoon YI, Park GC, Tak E. HIF-1α regulates A2B adenosine receptor expression in liver cancer cells. Exp Ther Med 2019;18:4231-40. [PMID: 31772626 DOI: 10.3892/etm.2019.8081] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Boušová I, Skálová L, Souček P, Matoušková P. The modulation of carbonyl reductase 1 by polyphenols. Drug Metabolism Reviews 2015;47:520-33. [DOI: 10.3109/03602532.2015.1089885] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
9 Tsochatzis E, Meyer T, O’beirne J, Burroughs AK. Transarterial chemoembolisation is not superior to embolisation alone: The recent European Association for the Study of the Liver (EASL)–European Organisation for Research and Treatment of Cancer (EORTC) guidelines. European Journal of Cancer 2013;49:1509-10. [DOI: 10.1016/j.ejca.2012.11.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
10 Kim YN, Jung HY, Eum WS, Kim DW, Shin MJ, Ahn EH, Kim SJ, Lee CH, Yong JI, Ryu EJ, Park J, Choi JH, Hwang IK, Choi SY. Neuroprotective effects of PEP-1-carbonyl reductase 1 against oxidative-stress-induced ischemic neuronal cell damage. Free Radic Biol Med 2014;69:181-96. [PMID: 24440593 DOI: 10.1016/j.freeradbiomed.2014.01.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
11 Juengpanich S, Topatana W, Lu C, Staiculescu D, Li S, Cao J, Lin J, Hu J, Chen M, Chen J, Cai X. Role of cellular, molecular and tumor microenvironment in hepatocellular carcinoma: Possible targets and future directions in the regorafenib era. Int J Cancer 2020;147:1778-92. [PMID: 32162677 DOI: 10.1002/ijc.32970] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, Davies N, Williams E, Pereira SP, Hochhauser D, Mayer A, Gillmore R, O'Beirne J, Patch D, Burroughs AK. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer. 2013;108:1252-1259. [PMID: 23449352 DOI: 10.1038/bjc.2013.85] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 8.9] [Reference Citation Analysis]
13 Zhou L, Yang C, Zhong W, Wang Q, Zhang D, Zhang J, Xie S, Xu M. Chrysin induces autophagy-dependent ferroptosis to increase chemosensitivity to gemcitabine by targeting CBR1 in pancreatic cancer cells. Biochem Pharmacol 2021;193:114813. [PMID: 34673014 DOI: 10.1016/j.bcp.2021.114813] [Reference Citation Analysis]
14 Varatharajan S, Panetta JC, Abraham A, Karathedath S, Mohanan E, Lakshmi KM, Arthur N, Srivastava VM, Nemani S, George B, Srivastava A, Mathews V, Balasubramanian P. Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia. Cancer Chemother Pharmacol 2016;78:1051-8. [PMID: 27738808 DOI: 10.1007/s00280-016-3166-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
15 Miura T, Taketomi A, Nishinaka T, Terada T. Regulation of human carbonyl reductase 1 (CBR1, SDR21C1) gene by transcription factor Nrf2. Chem Biol Interact 2013;202:126-35. [PMID: 23247010 DOI: 10.1016/j.cbi.2012.11.023] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
16 Guo Y, Shen Y, Xia Y, Gu J. Association between CBR1 polymorphisms and NSCLC in the Chinese population. Oncol Lett 2017;14:6291-7. [PMID: 29113280 DOI: 10.3892/ol.2017.6926] [Reference Citation Analysis]
17 Bains OS, Szeitz A, Lubieniecka JM, Cragg GE, Grigliatti TA, Riggs KW, Reid RE. A Correlation between Cytotoxicity and Reductase-Mediated Metabolism in Cell Lines Treated with Doxorubicin and Daunorubicin. J Pharmacol Exp Ther 2013;347:375-87. [DOI: 10.1124/jpet.113.206805] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 5.7] [Reference Citation Analysis]
18 Zhou H, Fu LX, Li L, Chen YY, Zhu HQ, Zhou JL, Lv MX, Gan RZ, Zhang XX, Liang G. The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression. J Ethnopharmacol 2020;261:113118. [PMID: 32621953 DOI: 10.1016/j.jep.2020.113118] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Lim S, Shin JY, Jo A, K.r J, Nguyen MN, Choi TG, Kim J, Park J, Eun YG, Yoon K, Ha J, Kim SS. Carbonyl reductase 1 is an essential regulator of skeletal muscle differentiation and regeneration. The International Journal of Biochemistry & Cell Biology 2013;45:1784-93. [DOI: 10.1016/j.biocel.2013.05.025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
20 Rashid MA, Haque M, Akbar M. Detoxification of Carbonyl Compounds by Carbonyl Reductase in Neurodegeneration. In: Essa MM, Akbar M, Guillemin G, editors. The Benefits of Natural Products for Neurodegenerative Diseases. Cham: Springer International Publishing; 2016. pp. 355-65. [DOI: 10.1007/978-3-319-28383-8_19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
21 Shi SM, Di L. The role of carbonyl reductase 1 in drug discovery and development. Expert Opinion on Drug Metabolism & Toxicology 2017;13:859-70. [DOI: 10.1080/17425255.2017.1356820] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
22 Xie ZB, Ma L, Wang XB, Bai T, Ye JZ, Zhong JH, Li LQ. Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. Tumour Biol. 2014;35:8451-8459. [PMID: 25038916 DOI: 10.1007/s13277-014-2340-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
23 Cheng J, Gao F, Chen X, Wu J, Xing C, Lv Z, Xu W, Xie Q, Wu L, Ye S, Xie H, Zheng S, Zhou L. Prohibitin-2 promotes hepatocellular carcinoma malignancy progression in hypoxia based on a label-free quantitative proteomics strategy. Mol Carcinog 2014;53:820-32. [PMID: 23661548 DOI: 10.1002/mc.22040] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
24 Cinci L, Luceri C, Bigagli E, Carboni I, Paccosi S, Parenti A, Guasti D, Coronnello M. Development and characterization of an in vitro model of colorectal adenocarcinoma with MDR phenotype. Cancer Med 2016;5:1279-91. [PMID: 27016279 DOI: 10.1002/cam4.694] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
25 Tsochatzis EA, Fatourou E, O’Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol 2014; 20(12): 3069-3077 [PMID: 24695579 DOI: 10.3748/wjg.v20.i12.3069] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
26 Cancela M, Paes JA, Moura H, Barr JR, Zaha A, Ferreira HB. Unraveling oxidative stress response in the cestode parasite Echinococcus granulosus. Sci Rep 2019;9:15876. [PMID: 31685918 DOI: 10.1038/s41598-019-52456-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Devan AR, Kumar AR, Nair B, Anto NP, Muraleedharan A, Mathew B, Kim H, Nath LR. Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma. Pharmaceuticals (Basel) 2021;14:656. [PMID: 34358082 DOI: 10.3390/ph14070656] [Reference Citation Analysis]
28 Li S, Chen S, Dong Z, Song X, Li X, Huang Z, Li H, Huang L, Zhuang G, Lan R, Guo M, Li W, Saw PE, Zhang L. Concurrent silencing of TBCE and drug delivery to overcome platinum-based resistance in liver cancer. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.03.003] [Reference Citation Analysis]
29 Slemc L, Kunej T. Transcription factor HIF1A: downstream targets, associated pathways, polymorphic hypoxia response element (HRE) sites, and initiative for standardization of reporting in scientific literature. Tumour Biol 2016;37:14851-61. [PMID: 27644243 DOI: 10.1007/s13277-016-5331-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
30 Wang J, Li Y, Zhang C, Chen X, Zhu L, Luo T. A hypoxia-linked gene signature for prognosis prediction and evaluating the immune microenvironment in patients with hepatocellular carcinoma. Transl Cancer Res 2021;10:3979-92. [PMID: 35116696 DOI: 10.21037/tcr-21-741] [Reference Citation Analysis]
31 Pawar H, Kashyap MK, Sahasrabuddhe NA, Renuse S, Harsha HC, Kumar P, Sharma J, Kandasamy K, Marimuthu A, Nair B. Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery. Cancer Biol Ther. 2011;12:510-522. [PMID: 21743296 DOI: 10.4161/cbt.12.6.16833] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 6.5] [Reference Citation Analysis]
32 Zhan M, Wang H, Xu SW, Yang LH, Chen W, Zhao SX, Shen H, Liu Q, Yang RM, Wang J. Variants in oxidative stress-related genes affect the chemosensitivity through Nrf2-mediated signaling pathway in biliary tract cancer. EBioMedicine 2019;48:143-60. [PMID: 31590928 DOI: 10.1016/j.ebiom.2019.08.037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
33 Zhou S, Cao H, Zhao Y, Li X, Zhang J, Hou C, Ma Y, Wang Q. RACK1 promotes hepatocellular carcinoma cell survival via CBR1 by suppressing TNF-α-induced ROS generation. Oncol Lett 2016;12:5303-8. [PMID: 28105239 DOI: 10.3892/ol.2016.5339] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
34 Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. Hepatology 2013;57:1847-57. [PMID: 23299930 DOI: 10.1002/hep.26224] [Cited by in Crossref: 164] [Cited by in F6Publishing: 158] [Article Influence: 18.2] [Reference Citation Analysis]
35 Tak E, Jung DH, Kim SH, Park GC, Jun DY, Lee J, Jung BH, Kirchner VA, Hwang S, Song GW, Lee SG. Protective role of hypoxia-inducible factor-1α-dependent CD39 and CD73 in fulminant acute liver failure. Toxicol Appl Pharmacol 2017;314:72-81. [PMID: 27899277 DOI: 10.1016/j.taap.2016.11.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
36 Zhang J, Li P, Wang Y, Liu J, Zhang Z, Cheng W, Wang Y. Ameliorative effects of a combination of baicalin, jasminoidin and cholic acid on ibotenic acid-induced dementia model in rats. PLoS One 2013;8:e56658. [PMID: 23437202 DOI: 10.1371/journal.pone.0056658] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
37 Jo A, Choi TG, Jo YH, Jyothi K, Nguyen MN, Kim J, Lim S, Shahid M, Akter S, Lee S, Lee KH, Kim W, Cho H, Lee J, Shokat KM, Yoon K, Kang I, Ha J, Kim SS. Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment. Antioxidants & Redox Signaling 2017;26:70-83. [DOI: 10.1089/ars.2015.6457] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
38 Xu X, Ding Y, Pan T, Gao F, Huang X, Sun Q. CT-Guided 125I Brachytherapy in the Treatment of Hepatocellular Carcinoma Refractory to Conventional Transarterial Chemoembolization: A Pilot Study. Cancer Manag Res 2021;13:3317-26. [PMID: 33883943 DOI: 10.2147/CMAR.S305422] [Reference Citation Analysis]
39 Méndez-Blanco C, Fondevila F, García-Palomo A, González-Gallego J, Mauriz JL. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp Mol Med 2018;50:1-9. [PMID: 30315182 DOI: 10.1038/s12276-018-0159-1] [Cited by in Crossref: 90] [Cited by in F6Publishing: 94] [Article Influence: 22.5] [Reference Citation Analysis]
40 Bai X, Chen Y, Hou X, Huang M, Jin J. Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters. Drug Metab Rev 2016;48:541-67. [PMID: 27320238 DOI: 10.1080/03602532.2016.1197239] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 13.0] [Reference Citation Analysis]
41 Ebert B, Kisiela M, Maser E. Transcriptional regulation of human and murine short-chain dehydrogenase/reductases (SDRs) – an in silico approach. Drug Metabolism Reviews 2016;48:183-217. [DOI: 10.3109/03602532.2016.1167902] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
42 Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C, Liu S, Zhang Y. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α. PLoS One 2014;9:e115565. [PMID: 25531114 DOI: 10.1371/journal.pone.0115565] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 7.3] [Reference Citation Analysis]
43 Li L, Liu Y, Li H, Guo X, He X, Geng S, Zhao H, Peng X, Shi D, Xiong B, Zhou G, Zhao Y, Zheng C, Yang X. Rational design of temperature-sensitive blood-vessel-embolic nanogels for improving hypoxic tumor microenvironment after transcatheter arterial embolization. Theranostics 2018;8:6291-306. [PMID: 30613298 DOI: 10.7150/thno.28845] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
44 Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin 2017;38:614-22. [PMID: 28344323 DOI: 10.1038/aps.2017.5] [Cited by in Crossref: 282] [Cited by in F6Publishing: 262] [Article Influence: 56.4] [Reference Citation Analysis]
45 Méndez-Blanco C, Fondevila F, Fernández-Palanca P, García-Palomo A, Pelt JV, Verslype C, González-Gallego J, Mauriz JL. Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells. Cancers (Basel) 2019;11:E1984. [PMID: 31835431 DOI: 10.3390/cancers11121984] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
46 Tak E, Jun DY, Kim SH, Park GC, Lee J, Hwang S, Song GW, Lee SG. Upregulation of P2Y2 nucleotide receptor in human hepatocellular carcinoma cells. J Int Med Res 2016;44:1234-47. [PMID: 27807254 DOI: 10.1177/0300060516662135] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
47 Cortezon-Tamarit F, Sarpaki S, Calatayud DG, Mirabello V, Pascu SI. Applications of "Hot" and "Cold" Bis(thiosemicarbazonato) Metal Complexes in Multimodal Imaging. Chem Rec 2016;16:1380-97. [PMID: 27149900 DOI: 10.1002/tcr.201500292] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
48 Kwon JH, Lee J, Kim J, Kirchner VA, Jo YH, Miura T, Kim N, Song GW, Hwang S, Lee SG, Yoon YI, Tak E. Upregulation of Carbonyl Reductase 1 by Nrf2 as a Potential Therapeutic Intervention for Ischemia/ Reperfusion Injury during Liver Transplantation. Mol Cells 2019;42:672-85. [PMID: 31486328 DOI: 10.14348/molcells.2019.0003] [Cited by in F6Publishing: 2] [Reference Citation Analysis]